Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07623668 | Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research | PHASE3 | RECRUITING | 210 | — | — | May 28, 2026 | Dec 1, 2028 | Jun 3, 2026 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| Privosegtor | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Privosegtor | DRUG | Privosegtor (OCS-05) 3 mg/kg/day IV for 5 treatment days |
| Methylprednisolone | DRUG | Methylprednisolone 1 g/day IV for 5 treatment days |
| Placebo | OTHER | 0.9% sodium chloride (NaCl) solution IV for 5 treatment days |
Key Inclusion Criteria: * Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss. * Onset of visual loss symptoms in the previous 12 days before first administration of study treatment. Key Exclusion Criteria: \- Have a hist...